GILD Nov 2024 82.500 call
| Previous close | 0.4000 |
| Open | 0.3100 |
| Bid | 0.2700 |
| Ask | 0.4300 |
| Strike | 82.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3100 - 0.3100 |
| Contract range | N/A |
| Volume | |
| Open interest | 256 |
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
GuruFocus.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)
Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.
